Adverum Biotechnologies
We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.
We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.
Adverum Biotechnologies is a US-based biotechnology and pharmaceutical company founded in 2006. The company's mission revolves around establishing gene therapy as the new standard of care for prevalent ocular diseases to restore vision and prevent blindness.
Adverum Biotechnologies is focused on developing durable, single-administration therapies delivered in physicians' offices to eliminate the need for frequent ocular injections. The company is currently evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), as a one-time, intravitreal (IVT) injection for patients with neovascular or wet age-related macular degeneration.
The recent $127.50M Post-IPO Equity investment on 05 February 2024 has garnered the support of 5AM Ventures, Vivo Capital, Commodore Capital, Logos Capital, Samsara BioCapital, TCG Crossover, Venrock Healthcare Capital Partners, and Frazier Life Sciences. This substantial investment signifies confidence in Adverum's potential to revolutionize the standard of care for ocular diseases through gene therapy.
With a strong focus on innovation and societal impact, Adverum Biotechnologies is positioned to make a significant contribution to the treatment of vision-related ailments, aiming to transform the standard of care, preserve vision, and create a profound impact on a global scale.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $127.50M | 8 |
|
05 Feb 2024 |
| Post-IPO Equity | $217.00M | - | 11 Aug 2020 | |
| Post-IPO Equity | $69.00M | - | 08 Feb 2018 | |
| Post-IPO Equity | $50.00M | - | 10 Aug 2017 | |
| Post-IPO Equity | $130.50M | - | 08 Jan 2015 |
No recent news or press coverage available for Adverum Biotechnologies.
We care about your data, and we'd love to use cookies make your experience better.
